Vascular smooth muscle polyploidy and cardiac hypertrophy in genetic hypertension

Hypertension
Anna F DominiczakJ L Reid

Abstract

We studied the mechanisms responsible for vascular and cardiac hypertrophy in hypertension (pressure load and humoral and genetic factors) in two experimental approaches: (1) We carried out a cosegregation analysis to correlate cardiac and vascular hypertrophy with subphenotypes of blood pressure in an F2 generation of a cross between stroke-prone spontaneously hypertensive rats (SHRSP) and normotensive Wistar-Kyoto rats; (2) we treated 8-week-old SHRSP with perindopril, an angiotensin-converting enzyme inhibitor; losartan, an angiotensin type 1 receptor antagonist; or perindopril combined with a nitric oxide synthase inhibitor to investigate the relative contributions of blood pressure and angiotensin II to the pathogenesis of cardiac hypertrophy and vascular smooth muscle polyploidy. Vascular smooth muscle polyploidy was measured with flow cytometry DNA analysis. Cardiac hypertrophy was assessed by measuring the ratios of heart weight to body weight and left ventricle + septum weight to body weight. Blood pressure was measured with radiotelemetry in the F2 cosegregation experiment and with tail-cuff plethysmography in the pharmacological study. In the F2 rats, the best predictor of smooth muscle polyploidy by ANCOVA was systo...Continue Reading

References

Oct 22, 1979·The American Journal of Cardiology·E D Frohlich, R C Tarazi
Jan 1, 1977·International Review of Cytology·W Y Brodsky, I V Uryvaeva
Feb 1, 1991·Trends in Pharmacological Sciences·P B TimmermansW F Herblin
Jun 1, 1986·Hypertension·A H LichtensteinA V Chobanian
Apr 1, 1985·Clinical Science·J J Morton, D J Webb
Jun 1, 1994·Hypertension·N E RhalebO A Carretero
Jun 1, 1995·Journal of Hypertension·M J BlackG R Campbell
Dec 1, 1994·American Journal of Hypertension·X GirerdS Laurent
Oct 1, 1994·Clinical and Experimental Pharmacology & Physiology·L Brown, C Sernia
Mar 1, 1993·American Journal of Hypertension·M E Safar

❮ Previous
Next ❯

Citations

Feb 5, 2000·Life Sciences·R D MachadoS P Andrade
Mar 11, 2005·Canadian Journal of Physiology and Pharmacology·Denis DebloisPavel Hamet
Oct 18, 2000·The Journal of Clinical Investigation·M L HixonA Gualberto
Jul 15, 1998·Journal of Hypertension·P I Korner, G L Jennings
Sep 30, 2008·Trends in Endocrinology and Metabolism : TEM·Christian DellesAnna F Dominiczak
Jan 9, 2008·Journal of Cellular Physiology·Donald J McCrannKatya Ravid
Jul 1, 1997·Canadian Journal of Physiology and Pharmacology·A J HalaykoN L Stephens
Sep 27, 2000·The Journal of Biological Chemistry·M L HixonA Gualberto
Oct 3, 1999·Physiological Reviews·J Zicha, J Kunes
Oct 31, 1998·Journal of Hypertension·P HametJ Tremblay
Feb 12, 1998·The American Journal of Physiology·A M DevlinA F Dominiczak
Apr 9, 2021·Kidney International·Kyung LeeJohn Cijiang He

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.